Plasma protein N-glycome composition associates with postprandial lipaemic response
-
Published:2023-07-03
Issue:1
Volume:21
Page:
-
ISSN:1741-7015
-
Container-title:BMC Medicine
-
language:en
-
Short-container-title:BMC Med
Author:
Louca Panayiotis, Štambuk Tamara, Frkatović-Hodžić Azra, Nogal Ana, Mangino Massimo, Berry Sarah E., Deriš Helena, Hadjigeorgiou George, Wolf Jonathan, Vinicki Martina, Franks Paul W., Valdes Ana M., Spector Tim D., Lauc Gordan, Menni CristinaORCID
Abstract
Abstract
Background
A dysregulated postprandial metabolic response is a risk factor for chronic diseases, including type 2 diabetes mellitus (T2DM). The plasma protein N-glycome is implicated in both lipid metabolism and T2DM risk. Hence, we first investigate the relationship between the N-glycome and postprandial metabolism and then explore the mediatory role of the plasma N-glycome in the relationship between postprandial lipaemia and T2DM.
Methods
We included 995 individuals from the ZOE-PREDICT 1 study with plasma N-glycans measured by ultra-performance liquid chromatography at fasting and triglyceride, insulin, and glucose levels measured at fasting and following a mixed-meal challenge. Linear mixed models were used to investigate the associations between plasma protein N-glycosylation and metabolic response (fasting, postprandial (Cmax), or change from fasting). A mediation analysis was used to further explore the relationship of the N-glycome in the prediabetes (HbA1c = 39–47 mmol/mol (5.7–6.5%))–postprandial lipaemia association.
Results
We identified 36 out of 55 glycans significantly associated with postprandial triglycerides (Cmaxβ ranging from -0.28 for low-branched glycans to 0.30 for GP26) after adjusting for covariates and multiple testing (padjusted < 0.05). N-glycome composition explained 12.6% of the variance in postprandial triglycerides not already explained by traditional risk factors. Twenty-seven glycans were also associated with postprandial glucose and 12 with postprandial insulin. Additionally, 3 of the postprandial triglyceride–associated glycans (GP9, GP11, and GP32) also correlate with prediabetes and partially mediate the relationship between prediabetes and postprandial triglycerides.
Conclusions
This study provides a comprehensive overview of the interconnections between plasma protein N-glycosylation and postprandial responses, demonstrating the incremental predictive benefit of N-glycans. We also suggest a considerable proportion of the effect of prediabetes on postprandial triglycerides is mediated by some plasma N-glycans.
Funder
Chronic Disease Research Foundation Wellcome Trust European Structural and Investment Funds IRI "CardioMetabolic" grant
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, Capdevila J, Hadjigeorgiou G, Davies R, Al Khatib H, et al. Human postprandial responses to food and potential for precision nutrition. Nat Med. 2020;26(6):964–73. 2. Mazidi M, Valdes AM, Ordovas JM, Hall WL, Pujol JC, Wolf J, Hadjigeorgiou G, Segata N, Sattar N, Koivula R, et al. Meal-induced inflammation: postprandial insights from the Personalised REsponses to DIetary Composition Trial (PREDICT) study in 1000 participants. Am J Clin Nutr. 2021;114(3):1028–38. 3. Jackson KG, Poppitt SD, Minihane AM. Postprandial lipemia and cardiovascular disease risk: interrelationships between dietary, physiological and genetic determinants. Atherosclerosis. 2012;220(1):22–33. 4. Ajit Varki, Richard D. Cummings, Jeffrey D. Esko, Pamela Stanley, Gerald W. Hart, Markus Aebi, Debra Mohnen, Taroh Kinoshita, Nicolle H. Packer, James H. Prestegard et al. Essentials of Glycobiology. edn. Edited by Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, Aebi M, Mohnen D, Kinoshita T, Packer NH, Prestegard JH et al. Cold Spring Harbor: Cold Spring Harbor Laboratory Press Copyright © 2022 by the Consortium of Glycobiology Editors. La Jolla, California. Published by Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. 2022. 5. Ballout RA, Remaley AT. GlycA: a new biomarker for systemic inflammation and cardiovascular disease (CVD) risk assessment. J Lab Precis Med. 2020;5:17.
|
|